trending Market Intelligence /marketintelligence/en/news-insights/trending/qhvoLpMCOtZuqhGm3rx7Dw2 content esgSubNav
In This List

Medica Clinical Nord Q3 profit climbs 47.1% YOY

Podcast

Master of Risk | Episode 6: Masters of Risk-Jennifer Reynolds

Video

Supplier Risk Indicator™

Podcast

Private Markets 360 | Episode 6: Benchmarking private investment performance

Case Study

A European Bank Leverages an AIF Scorecard to Help Meet Basel Regulatory Requirements


Medica Clinical Nord Q3 profit climbs 47.1% YOY

MedicaNatumin AB (publ) said its normalized net income for the third quarter came to 1.6 million kronor, a rise of 47.1% from 1.1 million kronor in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin increased to 5.2% from 5.2% in the year-earlier period.

Total revenue increased 45.6% on an annual basis to 30.0 million kronor from 20.6 million kronor, and total operating expenses climbed 35.6% from the prior-year period to 27.4 million kronor from 20.2 million kronor.

Reported net income increased 75.0% on an annual basis to 2.8 million kronor, or 1 öre per share, from 1.6 million kronor, or 1 öre per share.

As of Oct. 27, US$1 was equivalent to 9.05 Swedish kronor.